Want to see IL:CANF full AI Analyst Report?
CANF Stock Chart & Stats
515.20
-10.10(-2.00%)
At close: 4:00 PM EDT
515.20
-10.10(-2.00%)
Day’s Range― - ―
52-Week Range299.00 - 3,000.00
Previous CloseN/A
Volume9.36K
Average Volume (3M)24.23K
Market Cap
₪18.47M
Enterprise Value-5.67M
Total Cash (Recent Filing)₪7.04M
Total Debt (Recent Filing)₪49.00K
Price to Earnings (P/E)―
Beta-0.50
Next Earnings
Apr 01, 2027EPS Estimate
-122.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.54
Shares Outstanding6,063,093
10 Day Avg. Volume8,973
30 Day Avg. Volume24,230
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.77
Price to Sales (P/S)35.39
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt limits interest burden and reduces near-term balance-sheet pressure while the company funds clinical development. This gives management more flexibility than a highly leveraged biotech, although ongoing losses still make external financing important.
High Gross MarginGross profit broadly matching revenue indicates that direct costs are not currently consuming the company’s small revenue base. If commercial revenue expands, this structure could support attractive contribution economics, though operating expenses remain the main constraint.
A3AR Drug PlatformA focused A3AR platform provides a consistent scientific foundation across multiple potential indications, including psoriasis, liver inflammation and cancer. Positive development or partnering outcomes in one program could support broader value from the same discovery strategy.
Bears Say
Minimal Declining RevenueThe company has not established a growing commercial revenue base, and the longer-term decline leaves little internal funding for clinical development. Continued dependence on development outcomes and external capital increases the business’s financial vulnerability over the next several quarters.
Persistent LossesDeep losses relative to the current revenue scale show that operating expenses substantially exceed the company’s economic base. Unless development programs generate licensing income or commercial sales, this cost structure is likely to remain a major drag on financial sustainability.
Cash Burn And Financing RiskSustained operating and free-cash-flow deficits mean the company cannot currently fund operations from internally generated cash. Shrinking equity reinforces the likelihood of future financing needs, which may constrain strategy and create dilution risk for existing shareholders.
Can Fite Bio News
CANF FAQ
What was Can-Fite BioPharma Ltd.’s price range in the past 12 months?
Can-Fite BioPharma Ltd. lowest stock price was 299.00 and its highest was 3000.00 in the past 12 months.
What is Can-Fite BioPharma Ltd.’s market cap?
Can-Fite BioPharma Ltd.’s market cap is ₪18.47M.
When is Can-Fite BioPharma Ltd.’s upcoming earnings report date?
Can-Fite BioPharma Ltd.’s upcoming earnings report date is Apr 01, 2027 which is in 169 days.
How were Can-Fite BioPharma Ltd.’s earnings last quarter?
Can-Fite BioPharma Ltd. released its earnings results on Sep 08, 2026. The company reported -190.534 earnings per share for the quarter, missing the consensus estimate of -50.707 by -139.827.
Is Can-Fite BioPharma Ltd. overvalued?
According to Wall Street analysts Can-Fite BioPharma Ltd.’s price is currently Overvalued.
Does Can-Fite BioPharma Ltd. pay dividends?
Can-Fite BioPharma Ltd. does not currently pay dividends.
What is Can-Fite BioPharma Ltd.’s EPS estimate?
Can-Fite BioPharma Ltd.’s EPS estimate is -122.92.
How many shares outstanding does Can-Fite BioPharma Ltd. have?
Can-Fite BioPharma Ltd. has 6,063,093 shares outstanding.
What happened to Can-Fite BioPharma Ltd.’s price movement after its last earnings report?
Can-Fite BioPharma Ltd. reported an EPS of -190.534 in its last earnings report, missing expectations of -50.707. Following the earnings report the stock price went down -5.668%.
Which hedge fund is a major shareholder of Can-Fite BioPharma Ltd.?
Currently, no hedge funds are holding shares in IL:CANF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. is an Israel-based, clinical-stage biopharmaceutical firm dedicated to developing small molecule therapeutic agents. Its research and development efforts are concentrated on addressing conditions such as cancer, various liver inflammatory diseases, and erectile dysfunction. The company's lead investigational compound, Piclidenoson, has progressed through successful completion of its Phase III clinical trial for psoriasis and a Phase II clinical trial for COVID-19. Another promising candidate, Namodenoson, is presently undergoing a Phase III trial for hepatocellular carcinoma and a Phase IIb trial for non-alcoholic steatohepatitis. Furthermore, CF602 is in its pre-clinical phase, with potential application for erectile dysfunction. Beyond drug development, Can-Fite also creates a commercial predictive biomarker blood test kit specifically for A3AR. The company maintains strategic partnerships, including a licensing and collaboration agreement with CMS Medical for the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. A separate collaborative venture with Univo Pharmaceuticals focuses on identifying and jointly developing specific cannabis component formulations intended for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Founded in 1994 as Can-Fite Technologies Ltd., the company rebranded to Can-Fite BioPharma Ltd. in January 2001, and operates from its headquarters in Petah Tikva, Israel.